Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pfizer Inc (NYSE:PFE)

33.77
Delayed Data
As of Jun 27
 -0.27 / -0.79%
Today’s Change
29.83
Today|||52-Week Range
37.39
+3.97%
Year-to-Date
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
Jun 27 / Zacks.com - Paid Partner Content
J&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study
Jun 20 / Zacks.com - Paid Partner Content
Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU
Jun 27 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Chevron, Pfizer, Boeing, 3M and Citigroup
Jun 20 / Zacks.com - Paid Partner Content
Epizyme Progressing Well on Two Lead Pipeline Candidates
Jun 26 / Zacks.com - Paid Partner Content
Top Stock Reports for Chevron, Pfizer & Boeing
Jun 19 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: Boeing Bags Big Orders at Paris Air Show; Wal-Mart to Buy Bonob...
Jun 23 / Zacks.com - Paid Partner Content
3 Biotech Stocks That More than Doubled Year to Date
Jun 19 / Zacks.com - Paid Partner Content
Biotech Movers: Regeneron Slides Back After Big Gains
Jun 23 / TheStreet.com - Paid Partner Content
Dow 30 Stock Roundup: GE Appoints Flannery as CEO; UTX, CAT Hike Dividends
Jun 16 / Zacks.com - Paid Partner Content
Samsung Could Sell More Drugs
Jun 23 / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
Jun 16 / Zacks.com - Paid Partner Content
15 Great Dividend Stocks to Own Should the Surging Stock Market Plunge This Summer
Jun 23 / TheStreet.com - Paid Partner Content
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
Jun 15 / Zacks.com - Paid Partner Content
Stocks to Fight Cancer: Why Immunotherapy Is a Gamechanger
Jun 22 / Zacks.com - Paid Partner Content
Acceleron (XLRN) Kidney Cancer Candidate Fails in Phase II
Jun 14 / Zacks.com - Paid Partner Content
Stock Market News for June 22, 2017
Jun 22 / Zacks.com - Paid Partner Content
Washington turmoil is proving a bitter pill for Pfizer
Jun 12 / FT.com - Paid Partner Content
Merck's Keytruda on a Roll: Can it Retain the Momentum?
Jun 22 / Zacks.com - Paid Partner Content
Big US pharma dealmaking plunges to five-year low
Jun 12 / FT.com - Paid Partner Content
FDA Commisoner Takes on Big Pharma
Jun 21 / TheStreet.com - Paid Partner Content
AstraZeneca faces up to its year of living dangerously
Jun 11 / FT.com - Paid Partner Content
Dems Roast Trump for Leaving Medicare Out of Drug Price Order
Jun 21 / TheStreet.com - Paid Partner Content
Pfizer raises US prices of 91 drugs by 20% in 2017
Jun 02 / FT.com - Paid Partner Content
Shire's (SHPG) ADHD Drug Mydayis Receives Approval in US
Jun 21 / Zacks.com - Paid Partner Content
PPG drops its 27bn pursuit of Dutch rival Akzo
Jun 01 / FT.com - Paid Partner Content
Small Cancer Biotech Space in Focus, 3 Stocks Up 100% & More
Jun 21 / Zacks.com - Paid Partner Content
It will cost more than a coffee to recast BA as a favourite flier
May 30 / FT.com - Paid Partner Content
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
Jun 20 / Zacks.com - Paid Partner Content